Keros Therapeutics (KROS) Insider Trading & Ownership $10.79 -0.20 (-1.82%) Closing price 04:00 PM EasternExtended Trading$10.80 +0.01 (+0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Keros Therapeutics (NASDAQ:KROS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.90%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$11.00 M Get KROS Insider Trade Alerts Want to know when executives and insiders are buying or selling Keros Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KROS Insider Buying and Selling by Quarter Remove Ads Keros Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/13/2024Carl L GordonDirectorSell250,000$44.01$11,002,500.00 (Data available from 1/1/2013 forward) KROS Insider Trading Activity - Frequently Asked Questions Who is on Keros Therapeutics's Insider Roster? The list of insiders at Keros Therapeutics includes Carl L Gordon, Christopher Rovaldi, Jennifer Lachey, and Keith Regnante. Learn more on insiders at KROS. What percentage of Keros Therapeutics stock is owned by insiders? 22.90% of Keros Therapeutics stock is owned by insiders. Learn more on KROS's insider holdings. Which Keros Therapeutics insiders have been selling company stock? The following insiders have sold KROS shares in the last 24 months: Carl L Gordon ($11,002,500.00), and Keith Regnante ($955,800.00). How much insider selling is happening at Keros Therapeutics? Insiders have sold a total of 270,000 Keros Therapeutics shares in the last 24 months for a total of $11,958,300.00 sold. Keros Therapeutics Key ExecutivesDr. Jasbir S. Seehra Ph.D. (Age 68)President, CEO & Director Compensation: $1.13MMr. Keith C. Regnante MBA (Age 54)Chief Financial Officer Compensation: $636.11kMr. Christopher Rovaldi M.Sc. (Age 49)Chief Operating Officer Compensation: $784.9kMs. Esther Cho J.D.Senior VP, General Counsel & SecretaryMs. Robin WagnerSenior Vice President of Human ResourcesMr. John Oram M.B.A.Senior Vice President of Program & Portfolio Management More Insider Trading Tools from MarketBeat Related Companies IRON Insider Transactions AGIO Insider Transactions APGE Insider Transactions VERA Insider Transactions KNSA Insider Transactions SDGR Insider Transactions IDYA Insider Transactions WVE Insider Transactions IMCR Insider Transactions ANIP Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:KROS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
